Elo Mutual Pension Insurance Co Has $18.33 Million Position in Gilead Sciences, Inc. $GILD

Elo Mutual Pension Insurance Co raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.1% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 165,116 shares of the biopharmaceutical company’s stock after acquiring an additional 5,038 shares during the quarter. Elo Mutual Pension Insurance Co’s holdings in Gilead Sciences were worth $18,328,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Csenge Advisory Group raised its holdings in shares of Gilead Sciences by 319.0% during the third quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company’s stock worth $2,375,000 after acquiring an additional 16,288 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its holdings in Gilead Sciences by 52.1% during the 3rd quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 78,494 shares of the biopharmaceutical company’s stock worth $8,713,000 after purchasing an additional 26,882 shares in the last quarter. Cookson Peirce & Co. Inc. lifted its holdings in shares of Gilead Sciences by 249.1% in the third quarter. Cookson Peirce & Co. Inc. now owns 10,045 shares of the biopharmaceutical company’s stock valued at $1,115,000 after purchasing an additional 7,168 shares in the last quarter. Railway Pension Investments Ltd boosted its position in shares of Gilead Sciences by 3.1% during the third quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company’s stock worth $157,139,000 after buying an additional 42,200 shares during the period. Finally, TriaGen Wealth Management LLC bought a new position in shares of Gilead Sciences during the third quarter worth about $1,274,000. Institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $170.00 price target on shares of Gilead Sciences in a research report on Monday, February 23rd. Truist Financial boosted their price objective on shares of Gilead Sciences from $145.00 to $152.00 and gave the stock a “buy” rating in a research report on Wednesday, February 11th. Sanford C. Bernstein reiterated an “outperform” rating and issued a $160.00 price target on shares of Gilead Sciences in a research note on Wednesday, February 11th. HSBC increased their price objective on shares of Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a research note on Wednesday, December 10th. Finally, Royal Bank Of Canada upped their target price on Gilead Sciences from $103.00 to $118.00 and gave the stock a “sector perform” rating in a report on Wednesday, February 11th. Twenty-three research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $156.72.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead highlighted a twice-yearly HIV prevention injection with reported 99.9% efficacy (executive interview), reinforcing the company’s long-acting HIV/IP prevention market potential and upside to future sales if uptake and approvals follow. Johanna Mercier on Gilead’s HIV prevention innovation
• Positive Sentiment: New Phase 3 ARTISTRY-1 and ARTISTRY-2 data show the investigational single-tablet bictegravir/lenacapavir (BIC/LEN) maintained virological suppression when patients switched regimens — strengthens pipeline value and switch-market potential. Gilead’s Single-Tablet Regimen Maintained Virological Suppression
• Positive Sentiment: Daiwa raised its price target to $161 and kept an “outperform” rating, signaling buy-side confidence and giving shares technical/analyst momentum. Daiwa Securities Adjusts Price Target on Gilead Sciences
• Positive Sentiment: UBS reiterated a Buy with a $175 target, citing the advancing long-acting HIV franchise — another supportive analyst endorsement for upside. Gilead Sciences: Advancing Long-Acting HIV Franchise
• Positive Sentiment: Zacks issued a series of upward revisions to Gilead’s FY2026–FY2028 and multiple quarterly EPS forecasts (raises across 2026–2028), which supports higher medium-term earnings expectations. Zacks Research GILD Estimates
• Neutral Sentiment: Coverage pieces note Gilead has been outperforming the healthcare sector recently and analysts remain optimistic — supports momentum but is descriptive rather than new fundamental news. Gilead Sciences Stock: Is GILD Outperforming the Healthcare Sector?
• Neutral Sentiment: Industry/peer updates such as Kymera’s results were reported but are not directly material to Gilead’s near-term outlook. Kymera Therapeutics Q4 Highlights
• Negative Sentiment: Zacks trimmed its Q3 2026 EPS estimate slightly (from $2.34 to $2.30) — a small near-term downgrade within otherwise stronger multi-year raises; worth monitoring for quarterly variability. Zacks Lowers Q3 2026 Estimate
• Negative Sentiment: Merck reported promising Phase 3 results for a two-drug HIV regimen that matched Gilead’s Biktarvy, representing competitive pressure if approved. Investors should monitor regulatory outcomes and market-share implications. Merck’s New HIV Drug Shows Promise

Gilead Sciences Trading Up 3.6%

Shares of NASDAQ:GILD opened at $148.95 on Monday. Gilead Sciences, Inc. has a 52-week low of $93.37 and a 52-week high of $157.29. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55. The company has a market capitalization of $184.91 billion, a P/E ratio of 22.00, a price-to-earnings-growth ratio of 1.95 and a beta of 0.36. The company has a 50-day simple moving average of $136.10 and a 200 day simple moving average of $124.84.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The firm had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. During the same quarter in the prior year, the company earned $1.90 earnings per share. The business’s revenue for the quarter was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be issued a dividend of $0.82 per share. The ex-dividend date of this dividend is Friday, March 13th. This represents a $3.28 annualized dividend and a yield of 2.2%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s payout ratio is 46.68%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $154.43, for a total value of $463,290.00. Following the transaction, the chief financial officer directly owned 167,779 shares of the company’s stock, valued at $25,910,110.97. This represents a 1.76% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $154.44, for a total transaction of $4,324,320.00. Following the sale, the insider owned 120,288 shares of the company’s stock, valued at $18,577,278.72. This trade represents a 18.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 299,280 shares of company stock valued at $42,487,570. 0.27% of the stock is owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.